NexGard Combo spot-on solution for cats < 2.5 kg, 3x0.3 ml
196,50 lei
Unit price perEctoparasites
- Treatment of flea infestations (Ctenocephalides felis). One treatment provides immediate and persistent flea killing activity for one month.
- The product can be part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- Treatment of tick infestations. One treatment provides immediate and persistent tick killing activity against Ixodes scapularis for one month and against Ixodes ricinus for five weeks.
- Treatment of ear mite infestation (Otodectes cynotis).
Cestodes
Treatment of tapeworm infections (Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis, Joyeuxiella pasqualei and Joyeuxiella fuhrmanni).
Nematodes
- Prevention of heartworm disease (Dirofilaria immitis) for one month.
- Treatment of gastrointestinal nematode infections (L3, L4 larvae and adults of Toxocara cati,
L4 larvae and adults of Ancyclostoma tubaeforme and Ancyclostoma ceylanicum and adult forms of
Toxascaris leonina and Ancyclostoma braziliense).
- Treatment of feline lungworm infections (L4 larvae and adults of Troglostrongylus
brevior).
- Treatment of bladder worm infections (Capillaria plica).
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
ADVERSE REACTIONS
In clinical studies, hypersalivation, diarrhoea, transient skin reactions at the application site (local alopecia, pruritus), anorexia, lethargy and emesis were uncommonly observed shortly after administration. Most reactions are mild, short-lived and self-limiting.
The frequency of adverse reactions is defined using the following convention:
- Very common (more than 1 in 10 treated animals showing adverse reactions)
- Common (more than 1 but less than 10 animals in 100 treated animals)
- Uncommon (more than 1 but less than 10 animals in 1,000 treated animals)
- Rare (more than 1 but less than 10 animals in 10,000 treated animals)
- Very rare (less than 1 animal in 10,000 treated animals, including isolated reports).
If you notice any adverse reactions, even those not already listed in this package leaflet, or believe the medicinal product has not been effective, please inform your veterinary surgeon.
Dosage
The minimum recommended doses are 1.44 mg esafoxolaner, 0.48 mg eprinomectin and 10 mg praziquantel per kg body weight.
RECOMMENDATIONS FOR CORRECT ADMINISTRATION
Use the applicator sized according to the cat's weight (0.3 or 0.9 ml, see "declaration of active substance(s) and other ingredients" section)
1. Use scissors to cut the blister along the dotted line, then peel off the foil.
2. Remove the applicator from the packaging and hold it upright.
3. Slowly pull back the plunger, twist and remove the cap.
4. Part the fur in the middle of the neck, between the base of the skull and the shoulder blades, so that the skin is visible.
5. Place the tip of the applicator on the skin and apply the entire contents directly onto the skin in one spot.
The product should be applied to dry skin in an area where the cat cannot lick it off. In long-haired breeds, extra care should be taken to apply the product directly to the skin and not to the fur to ensure optimal efficacy.
Treatment schedule:
For the treatment of flea and/or tick and/or ear mite infestations and the concomitant treatment of gastrointestinal and/or pulmonary and/or bladder nematodes and cestodes, a single dose of the product should be applied. The necessity and frequency of treatment(s) should be in accordance with the veterinary surgeon's advice and take into account the local epidemiological situation and the animal's lifestyle (e.g., whether it has outdoor access).
Endemic areas without cardiovascular heartworm disease:
Cats not at permanent risk of heartworm infection should be treated according to a program prescribed by the veterinary surgeon, adapted to each individual situation of re-infection/parasite infestation. Otherwise, a product with a narrower spectrum of action that provides appropriate treatment against relevant parasites should be used.
Endemic areas with cardiovascular heartworm disease:
Cats living in areas endemic for cardiovascular heartworm disease and recognized as hunters may be treated at monthly intervals to ensure adequate prevention against cardiovascular heartworm disease and treatment of possible cestode re-infection. Otherwise, a product with a narrower spectrum of action should be used for continued treatment. Prevention of cardiovascular heartworm disease by killing Dirofilaria immitis larvae should begin within one month
after the first exposure to mosquitoes and continue until 1 month after the last exposure to mosquitoes.
Ear mites
In case of ear mites, request a new veterinary examination 4 weeks after treatment to
decide if additional treatment with a product with a narrower spectrum of action is necessary.
SPECIAL PRECAUTIONS FOR STORAGE
Keep out of the sight and reach of children.
Keep unused applicators in the original packaging to protect from light.
Opened applicators must be disposed of immediately as waste.
Do not use this veterinary medicinal product after the expiry date marked on the box after EXP.
SPECIAL WARNINGS
Special precautions for the target species:
Avoid shampooing the animal within 2 days after administration as the efficacy of the product in this case has not been tested.
Ticks and fleas must start feeding on the cat to be exposed to esafoxolaner, therefore the risk of arthropod-borne disease transmission cannot be excluded.
Cats living in heartworm endemic areas or those that have travelled to such areas, may be infected with adult heartworms. Although the product can be safely administered to cats infected with adult heartworms, no therapeutic effect against adult Dirofilaria immitis heartworms has been established. Therefore, it is recommended that all cats 6 months of age or older, living in heartworm endemic areas, be tested for adult heartworm infection before being treated with the product for heartworm prevention.
Tapeworm infection may recur if intermediate hosts such as fleas, mice etc. are not controlled. Some cats in the patent period of Joyeuxiella spp. or Dipylidium caninum infection may still have high proportions of young parasite forms which may be less sensitive to this product; therefore, post-treatment monitoring is recommended for these infections.
Resistance of parasites to a particular class of antiparasitic drugs can develop as a result of repeated use of a compound from that class over an extended period. Therefore, epidemiological information regarding the current susceptibility of the target species should be considered to limit the possibility of future selection of resistance.
To reduce re-infestations once new fleas appear, it is recommended that all cats in the household be treated. Any other animal species living in the same household should be treated with a product intended for them.
Fleas in any of their developmental stages can infest a cat's basket, bedding and usual resting areas, such as carpets and soft furnishings. In cases of major infestations and before implementing control measures, these areas should be treated with an appropriate product and regularly vacuumed.
Special precautions for use in animals
For spot-on application only. Do not inject, administer orally or by any other route. Avoid contact with the cat's eyes. In case of accidental ocular exposure, immediately rinse the eye area with clean water. If ocular irritation persists, seek veterinary advice.
It is very important that the veterinary medicinal product is applied to the skin in an area where the cat cannot lick the product, in the posterior region of the neck, between the shoulders. Ensure that animals do not lick each other until the treated area is no longer visible. Oral ingestion of the veterinary medicinal product has been observed to cause hypersalivation in cats.
The safety of the veterinary medicinal product has not been tested in kittens under 8 weeks of age. The product should not be used in cats weighing less than 0.8 kg and/or less than 8 weeks of age.
The veterinary medicinal product should be used exclusively against confirmed mixed infections or if cats are at significant risk of such mixed infections with ectoparasites and nematodes (including for heartworm prevention) and when treatment against cestodes is indicated at the same time. In the absence of co-infestation risk, an antiparasitic with a narrower spectrum of action should be used as a first-line treatment.
The reason for prescribing and the frequency of use of this product should take into account the individual needs of the cat based on clinical assessment, the animal's lifestyle and the epidemiological situation (including zoonotic risk, if relevant) so that the decision to use it is taken exclusively in situations of infection or risk of combined infection.
The veterinary medicinal product should not be used in other cats without prior veterinary consultation.
Repeated treatments should be limited to specific individual situations (see treatment application recommendations in the "Recommendations for correct administration" section) with a minimum interval between treatments of 4 weeks. Safety has not been evaluated beyond 6 months (see also "Special precautions for the target species" and "Overdose" sections), therefore a maximum of 6 consecutive months of treatment in a 12-month period is recommended.
Echinococcosis represents a risk to humans and is one of the diseases monitored by the World Organisation for Animal Health (OIE). In cases of echinococcosis, specific treatment, monitoring, and human protection regulations must be followed. Experts or parasitology institutes should be consulted.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Do not smoke, drink or eat while handling the product.
Wash hands immediately after use.
Used applicators should be disposed of immediately and should not be left within the sight or reach of children.
Avoid finger contact with the contents of the applicator. If this occurs, wash with soap and water. This veterinary medicinal product may cause eye irritation which, in exceptional cases, can be severe. In case of accidental eye contact, rinse immediately and thoroughly with water. Remove contact lenses, if worn, within the first 5 minutes and continue rinsing. Seek medical advice and show the product leaflet or label to the physician.
Ensure that the area where the product was applied is no longer visible before touching the application site. Children should not play with treated animals until the application site is no longer visible and it is recommended that recently treated animals do not sleep with owners, especially children. It is recommended to treat animals in the evening to reduce contact with people after treatment.
Persons with known hypersensitivity to esafoxolaner, eprinomectin or praziquantel or to any of the excipients should not handle this veterinary medicinal product.
As fetotoxic and teratogenic effects are described in laboratory animals following significant daily exposure to glycerol formal, pregnant women should wear gloves during administration to avoid direct contact with the product.
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. As fetotoxic and teratogenic effects are described in laboratory animals following significant daily exposure to glycerol formal, it should only be used in accordance with the veterinary surgeon's risk/benefit assessment.
Overdose :
Safety in use has been evaluated in healthy kittens, 8 weeks of age or older, that received up to 5 times the maximum recommended dose, treated up to 6 times, at 4-week intervals. No adverse reactions were observed at 3 times the maximum recommended dose. At 5 times the maximum recommended dose, a single severe neurological adverse reaction (ataxia, disorientation, apathy, tremor, hypothermia and pupil dilation) was observed after the third treatment and was reversible after washing the application site, emergency measures and symptomatic treatment. In some animals, at 5 times the maximum recommended dose, dark red subcutaneous areas were observed at the treatment application site.
NexGard Combo spot-on solution for cats < 2.5 kg, 3x0.3 ml
196,50 lei
Unit price perIn stock
196,50 lei
Unit price perEctoparasites
- Treatment of flea infestations (Ctenocephalides felis). One treatment provides immediate and persistent flea killing activity for one month.
- The product can be part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- Treatment of tick infestations. One treatment provides immediate and persistent tick killing activity against Ixodes scapularis for one month and against Ixodes ricinus for five weeks.
- Treatment of ear mite infestation (Otodectes cynotis).
Cestodes
Treatment of tapeworm infections (Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis, Joyeuxiella pasqualei and Joyeuxiella fuhrmanni).
Nematodes
- Prevention of heartworm disease (Dirofilaria immitis) for one month.
- Treatment of gastrointestinal nematode infections (L3, L4 larvae and adults of Toxocara cati,
L4 larvae and adults of Ancyclostoma tubaeforme and Ancyclostoma ceylanicum and adult forms of
Toxascaris leonina and Ancyclostoma braziliense).
- Treatment of feline lungworm infections (L4 larvae and adults of Troglostrongylus
brevior).
- Treatment of bladder worm infections (Capillaria plica).
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
ADVERSE REACTIONS
In clinical studies, hypersalivation, diarrhoea, transient skin reactions at the application site (local alopecia, pruritus), anorexia, lethargy and emesis were uncommonly observed shortly after administration. Most reactions are mild, short-lived and self-limiting.
The frequency of adverse reactions is defined using the following convention:
- Very common (more than 1 in 10 treated animals showing adverse reactions)
- Common (more than 1 but less than 10 animals in 100 treated animals)
- Uncommon (more than 1 but less than 10 animals in 1,000 treated animals)
- Rare (more than 1 but less than 10 animals in 10,000 treated animals)
- Very rare (less than 1 animal in 10,000 treated animals, including isolated reports).
If you notice any adverse reactions, even those not already listed in this package leaflet, or believe the medicinal product has not been effective, please inform your veterinary surgeon.
Dosage
The minimum recommended doses are 1.44 mg esafoxolaner, 0.48 mg eprinomectin and 10 mg praziquantel per kg body weight.
RECOMMENDATIONS FOR CORRECT ADMINISTRATION
Use the applicator sized according to the cat's weight (0.3 or 0.9 ml, see "declaration of active substance(s) and other ingredients" section)
1. Use scissors to cut the blister along the dotted line, then peel off the foil.
2. Remove the applicator from the packaging and hold it upright.
3. Slowly pull back the plunger, twist and remove the cap.
4. Part the fur in the middle of the neck, between the base of the skull and the shoulder blades, so that the skin is visible.
5. Place the tip of the applicator on the skin and apply the entire contents directly onto the skin in one spot.
The product should be applied to dry skin in an area where the cat cannot lick it off. In long-haired breeds, extra care should be taken to apply the product directly to the skin and not to the fur to ensure optimal efficacy.
Treatment schedule:
For the treatment of flea and/or tick and/or ear mite infestations and the concomitant treatment of gastrointestinal and/or pulmonary and/or bladder nematodes and cestodes, a single dose of the product should be applied. The necessity and frequency of treatment(s) should be in accordance with the veterinary surgeon's advice and take into account the local epidemiological situation and the animal's lifestyle (e.g., whether it has outdoor access).
Endemic areas without cardiovascular heartworm disease:
Cats not at permanent risk of heartworm infection should be treated according to a program prescribed by the veterinary surgeon, adapted to each individual situation of re-infection/parasite infestation. Otherwise, a product with a narrower spectrum of action that provides appropriate treatment against relevant parasites should be used.
Endemic areas with cardiovascular heartworm disease:
Cats living in areas endemic for cardiovascular heartworm disease and recognized as hunters may be treated at monthly intervals to ensure adequate prevention against cardiovascular heartworm disease and treatment of possible cestode re-infection. Otherwise, a product with a narrower spectrum of action should be used for continued treatment. Prevention of cardiovascular heartworm disease by killing Dirofilaria immitis larvae should begin within one month
after the first exposure to mosquitoes and continue until 1 month after the last exposure to mosquitoes.
Ear mites
In case of ear mites, request a new veterinary examination 4 weeks after treatment to
decide if additional treatment with a product with a narrower spectrum of action is necessary.
SPECIAL PRECAUTIONS FOR STORAGE
Keep out of the sight and reach of children.
Keep unused applicators in the original packaging to protect from light.
Opened applicators must be disposed of immediately as waste.
Do not use this veterinary medicinal product after the expiry date marked on the box after EXP.
SPECIAL WARNINGS
Special precautions for the target species:
Avoid shampooing the animal within 2 days after administration as the efficacy of the product in this case has not been tested.
Ticks and fleas must start feeding on the cat to be exposed to esafoxolaner, therefore the risk of arthropod-borne disease transmission cannot be excluded.
Cats living in heartworm endemic areas or those that have travelled to such areas, may be infected with adult heartworms. Although the product can be safely administered to cats infected with adult heartworms, no therapeutic effect against adult Dirofilaria immitis heartworms has been established. Therefore, it is recommended that all cats 6 months of age or older, living in heartworm endemic areas, be tested for adult heartworm infection before being treated with the product for heartworm prevention.
Tapeworm infection may recur if intermediate hosts such as fleas, mice etc. are not controlled. Some cats in the patent period of Joyeuxiella spp. or Dipylidium caninum infection may still have high proportions of young parasite forms which may be less sensitive to this product; therefore, post-treatment monitoring is recommended for these infections.
Resistance of parasites to a particular class of antiparasitic drugs can develop as a result of repeated use of a compound from that class over an extended period. Therefore, epidemiological information regarding the current susceptibility of the target species should be considered to limit the possibility of future selection of resistance.
To reduce re-infestations once new fleas appear, it is recommended that all cats in the household be treated. Any other animal species living in the same household should be treated with a product intended for them.
Fleas in any of their developmental stages can infest a cat's basket, bedding and usual resting areas, such as carpets and soft furnishings. In cases of major infestations and before implementing control measures, these areas should be treated with an appropriate product and regularly vacuumed.
Special precautions for use in animals
For spot-on application only. Do not inject, administer orally or by any other route. Avoid contact with the cat's eyes. In case of accidental ocular exposure, immediately rinse the eye area with clean water. If ocular irritation persists, seek veterinary advice.
It is very important that the veterinary medicinal product is applied to the skin in an area where the cat cannot lick the product, in the posterior region of the neck, between the shoulders. Ensure that animals do not lick each other until the treated area is no longer visible. Oral ingestion of the veterinary medicinal product has been observed to cause hypersalivation in cats.
The safety of the veterinary medicinal product has not been tested in kittens under 8 weeks of age. The product should not be used in cats weighing less than 0.8 kg and/or less than 8 weeks of age.
The veterinary medicinal product should be used exclusively against confirmed mixed infections or if cats are at significant risk of such mixed infections with ectoparasites and nematodes (including for heartworm prevention) and when treatment against cestodes is indicated at the same time. In the absence of co-infestation risk, an antiparasitic with a narrower spectrum of action should be used as a first-line treatment.
The reason for prescribing and the frequency of use of this product should take into account the individual needs of the cat based on clinical assessment, the animal's lifestyle and the epidemiological situation (including zoonotic risk, if relevant) so that the decision to use it is taken exclusively in situations of infection or risk of combined infection.
The veterinary medicinal product should not be used in other cats without prior veterinary consultation.
Repeated treatments should be limited to specific individual situations (see treatment application recommendations in the "Recommendations for correct administration" section) with a minimum interval between treatments of 4 weeks. Safety has not been evaluated beyond 6 months (see also "Special precautions for the target species" and "Overdose" sections), therefore a maximum of 6 consecutive months of treatment in a 12-month period is recommended.
Echinococcosis represents a risk to humans and is one of the diseases monitored by the World Organisation for Animal Health (OIE). In cases of echinococcosis, specific treatment, monitoring, and human protection regulations must be followed. Experts or parasitology institutes should be consulted.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Do not smoke, drink or eat while handling the product.
Wash hands immediately after use.
Used applicators should be disposed of immediately and should not be left within the sight or reach of children.
Avoid finger contact with the contents of the applicator. If this occurs, wash with soap and water. This veterinary medicinal product may cause eye irritation which, in exceptional cases, can be severe. In case of accidental eye contact, rinse immediately and thoroughly with water. Remove contact lenses, if worn, within the first 5 minutes and continue rinsing. Seek medical advice and show the product leaflet or label to the physician.
Ensure that the area where the product was applied is no longer visible before touching the application site. Children should not play with treated animals until the application site is no longer visible and it is recommended that recently treated animals do not sleep with owners, especially children. It is recommended to treat animals in the evening to reduce contact with people after treatment.
Persons with known hypersensitivity to esafoxolaner, eprinomectin or praziquantel or to any of the excipients should not handle this veterinary medicinal product.
As fetotoxic and teratogenic effects are described in laboratory animals following significant daily exposure to glycerol formal, pregnant women should wear gloves during administration to avoid direct contact with the product.
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. As fetotoxic and teratogenic effects are described in laboratory animals following significant daily exposure to glycerol formal, it should only be used in accordance with the veterinary surgeon's risk/benefit assessment.
Overdose :
Safety in use has been evaluated in healthy kittens, 8 weeks of age or older, that received up to 5 times the maximum recommended dose, treated up to 6 times, at 4-week intervals. No adverse reactions were observed at 3 times the maximum recommended dose. At 5 times the maximum recommended dose, a single severe neurological adverse reaction (ataxia, disorientation, apathy, tremor, hypothermia and pupil dilation) was observed after the third treatment and was reversible after washing the application site, emergency measures and symptomatic treatment. In some animals, at 5 times the maximum recommended dose, dark red subcutaneous areas were observed at the treatment application site.
